NVO 今日盤勢平淡，NILE 評分維持 66.2，無變動。
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
部分因子當期缺資料，其權重已按比例分攤到其餘因子，不計為 0 分。
| 因子 | 數值 | 單項得分 | 因子排名 | 權重 | 貢獻分 | 來源 |
|---|---|---|---|---|---|---|
| 護城河編輯評定 | 74 | 74 | #29 | 41.7 | 30.8 | NILE 編輯評定 |
| 未來成長率編輯評定 | 5.0% | 45 | #61 | 32.1 | 14.5 | NILE 編輯預估 |
| 估值（預估本益比）財報計算 | 15.0x | 80 | #7 | 26.2 | 20.9 | 最近一期財報與收盤價 |
| 自由現金流利潤率財報計算 | — | — | — | 0.0 | 0.0 | 最近一期財報 |
評分為資料整理與分析觀點，非投資建議，不構成任何買賣要約。